New hope drug enters human testing for tough cancers
NCT ID NCT06783569
Summary
This is the first study testing the experimental drug JR8603 in people. It aims to find a safe dose and see if it helps control advanced solid tumors, particularly stomach, esophageal junction, and colorectal cancers, when standard treatments have stopped working. The study will enroll about 94 adults and involves receiving the drug through an IV infusion three times per month.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heiljiang Province, 150040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Liaoning Cancer Hospital
RECRUITINGShenyang, Liaoning, 110042, China
Contact
Conditions
Explore the condition pages connected to this study.